[CAS NO. 221877-54-9] Zotarolimus

Ships within

Stock

Price

Qty

Total

$0.00

Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis

request a quote

If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [221877-54-9]

Catalog

HY-12424

Brand

MCE

CAS

221877-54-9

DESCRIPTION [221877-54-9]

Overview

MDL	-
Molecular Weight	966.21
Molecular Formula	C52H79N5O12
SMILES	CO[C@H]1[C@@H](N2C=NN=N2)CC[C@@H](C[C@H]([C@@](CC([C@@H](/C=C([C@H]([C@H](C([C@@H](C[C@@H]3C)C)=O)OC)O)\C)C)=O)([H])OC([C@@](CCCC4)([H])N4C(C([C@](O[C@]5([H])C[C@@H](/C(C)=C/C=C/C=C/3)OC)([C@@H](CC5)C)O)=O)=O)=O)C)C1

For research use only. We do not sell to patients.

2 Publications Citing Use of MCE

Summary

Zotarolimus (ABT-578) is a derivative of rapamycin (HY-10219), with anti-proliferative activity. Zotarolimus is an immunosuppressant. Zotarolimus is developed specifically for local delivery from stents for the prevention of coronary artery restenosis ^[1] ^[2] .

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase
NCT01347554	Yonsei University\|Medtronic	Myocardial Infarction	January 2009	Phase 4
NCT02098876	Emory University\|Medtronic	Coronary Artery Disease	May 2014	Not Applicable
NCT00623441	Medtronic Bakken Research Center\|Medtronic Cardiovascular	Coronary Artery Disease	September 2005
NCT05209412	Xijing Hospital	De Novo Stenosis\|Coronary Artery Disease\|Percutaneous Coronary Intervention	February 1, 2022	Not Applicable
NCT00846846	Medtronic Vascular	Coronary Artery Disease, Autosomal Dominant, 1	January 2009	Phase 4
NCT01133925	A.O. Ospedale Papa Giovanni XXIII\|Case Western Reserve University\|Medtronic Vascular	Coronary Artery Disease	May 2008	Phase 4
NCT01200693	Catholic University of the Sacred Heart	Coronary Artery Disease\|Coronary Stenosis	November 2008	Phase 4
NCT01385319	Marco Valgimigli\|Università degli Studi di Ferrara	Coronary Artery Disease	June 2011	Phase 3
NCT00693030	A.O. Ospedale Papa Giovanni XXIII\|Case Western Reserve University\|Medtronic Vascular\|Boston Scientific Corporation	Coronary Artery Disease	August 2006	Phase 4
NCT00894062	Yonsei University\|Medtronic Vascular	Coronary Artery Disease	December 2008	Phase 4
NCT03056118	Gangnam Severance Hospital	Ischemic Heart Disease	May 2, 2011	Phase 4
NCT05240781	Instituto Nacional de Cardiologia Ignacio Chavez	High Bleeding Risk\|Coronary Artery Disease\|Percutaneous Coronary Intervention	September 29, 2021	Not Applicable

Appearance

Solid

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Solvent & Solubility

In Vitro:

DMSO : 100 mg/mL ( 103.50 mM ; Need ultrasonic)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	1.0350 mL	5.1749 mL	10.3497 mL
5 mM	0.2070 mL	1.0350 mL	2.0699 mL
10 mM	0.1035 mL	0.5175 mL	1.0350 mL

* Please refer to the solubility information to select the appropriate solvent.

In Vivo:

1.

Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline

Solubility: 2.5 mg/mL (2.59 mM); Suspended solution; Need ultrasonic
2.

Add each solvent one by one: 10% DMSO >> 90% corn oil

Solubility: ≥ 2.5 mg/mL (2.59 mM); Clear solution

* All of the co-solvents are available by MCE.

References

Synonyms

Rapamycin, 42-deoxy-42-(1H-tetrazol-1-yl)-, (42S)-

(42S)-42-Deoxy-42-(1H-tetrazol-1-yl)rapamycin

A 179578

ABT 578

Zotarolimus

42-(1-Tetrazolyl)rapamycin

Resolute

Endeavor